251 related articles for article (PubMed ID: 12709045)
1. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective.
Björkman S
Haemophilia; 2003 May; 9 Suppl 1():101-8; discussion 109-10. PubMed ID: 12709045
[TBL] [Abstract][Full Text] [Related]
2. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
Ahnström J; Berntorp E; Lindvall K; Björkman S
Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
[TBL] [Abstract][Full Text] [Related]
3. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
Björkman S; Folkesson A; Berntorp E
Haemophilia; 2007 Jan; 13(1):2-8. PubMed ID: 17212717
[TBL] [Abstract][Full Text] [Related]
4. Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis.
Carlsson M; Björkman S; Berntorp E
Haemophilia; 1998 Mar; 4(2):83-8. PubMed ID: 9873843
[TBL] [Abstract][Full Text] [Related]
5. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia.
Collins PW; Fischer K; Morfini M; Blanchette VS; Björkman S;
Haemophilia; 2011 Jan; 17(1):2-10. PubMed ID: 20731726
[TBL] [Abstract][Full Text] [Related]
6. Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT).
Jeanpierre E; Pouplard C; Lasne D; Le Cam Duchez V; Eschwege V; Flaujac C; Galinat H; Harzallah I; Proulle V; Smahi M; Sobas F; Stepina N; Toulon P; Voisin S; Ternisien C; Nougier C;
Eur J Haematol; 2020 Aug; 105(2):103-115. PubMed ID: 32277501
[TBL] [Abstract][Full Text] [Related]
7. Prevention and Management of Bleeding Episodes in Children with Hemophilia.
Ljung RCR
Paediatr Drugs; 2018 Oct; 20(5):455-464. PubMed ID: 30128815
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis.
Björkman S; Shapiro AD; Berntorp E
Haemophilia; 2001 Mar; 7(2):133-9. PubMed ID: 11260271
[TBL] [Abstract][Full Text] [Related]
9. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens.
Collins PW; Björkman S; Fischer K; Blanchette V; Oh M; Schroth P; Fritsch S; Casey K; Spotts G; Ewenstein BM
J Thromb Haemost; 2010 Feb; 8(2):269-75. PubMed ID: 19943875
[TBL] [Abstract][Full Text] [Related]
10. Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia.
Shapiro AD; Korth-Bradley J; Poon MC
Haemophilia; 2005 Nov; 11(6):571-82. PubMed ID: 16236106
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic dosing in prophylactic treatment of hemophilia A.
Carlsson M; Berntorp E; Björkman S; Lindvall K
Eur J Haematol; 1993 Oct; 51(4):247-52. PubMed ID: 8243614
[TBL] [Abstract][Full Text] [Related]
12. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
Mahdi AJ; Obaji SG; Collins PW
Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of recombinant factor IX: implications for dose tailoring.
Björkman S
Haemophilia; 2013 Sep; 19(5):753-7. PubMed ID: 23731351
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.
Björkman S; Berntorp E
Clin Pharmacokinet; 2001; 40(11):815-32. PubMed ID: 11735604
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A.
Björkman S; Folkesson A; Jönsson S
Eur J Clin Pharmacol; 2009 Oct; 65(10):989-98. PubMed ID: 19557401
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of factor VIII and factor IX.
Morfini M
Haemophilia; 2003 May; 9 Suppl 1():94-9; discussion 100. PubMed ID: 12709044
[TBL] [Abstract][Full Text] [Related]
17. Aspects of haemophilia prophylaxis in Sweden.
Ljung RC
Haemophilia; 2002 Mar; 8 Suppl 2():34-7. PubMed ID: 11966851
[TBL] [Abstract][Full Text] [Related]
18. When should prophylactic treatment in patients with haemophilia A and B start?--The German experience.
Kreuz W; Escuriola-Ettingshausen C; Funk M; Schmidt H; Kornhuber B
Haemophilia; 1998 Jul; 4(4):413-7. PubMed ID: 9873763
[TBL] [Abstract][Full Text] [Related]
19. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring.
Björkman S; Blanchette VS; Fischer K; Oh M; Spotts G; Schroth P; Fritsch S; Patrone L; Ewenstein BM; ; Collins PW
J Thromb Haemost; 2010 Apr; 8(4):730-6. PubMed ID: 20398185
[TBL] [Abstract][Full Text] [Related]
20. The "OPTI-CLOT" trial. A randomised controlled trial on periOperative PharmacokineTIc-guided dosing of CLOTting factor concentrate in haemophilia A.
Hazendonk HC; van Moort I; Fijnvandraat K; Kruip MJ; Laros-van Gorkom BA; van der Meer FJ; Meijer K; Peters M; Schutgens RE; Zwaan CM; Driessens MH; Polinder S; Leebeek FW; Mathôt RA; Cnossen MH
Thromb Haemost; 2015 Aug; 114(3):639-44. PubMed ID: 26062822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]